Fresenius properly cancelled Akorn deal, court rules

Healthcare company Fresenius did not breach its merger agreement with rival pharmaceutical company Akorn when it decided to terminate the $4.3 billion deal, Delaware’s Court of Chancery has ruled.

Get unlimited access to all Global Competition Review content